Clinical trial will test long acting HIV injection

05:04 EDT 10 May 2019 | Pharmafile

A long-acting, injectable HIV drug combo is to be tested in a clinical trial of 350 volunteers with HIV.

The LATITUDE trial will test the experimental two drug regimen – a combination of Janssen’s rilpivirine (RPV) with ViiV’s cabotegravir (CAB) – in patients who have in the past 18 months documented treatment relapses.

LATITUDE, short for ‘Long-Acting Therapy to Improve Treatment Success in Daily Life’, will test the injectable combo’s effectiveness in managing HIV infections in the adult population.

read more

Original Article: Clinical trial will test long acting HIV injection


More From BioPortfolio on "Clinical trial will test long acting HIV injection"

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...